273 related articles for article (PubMed ID: 12810351)
1. Intestinal tissue kallikrein-kallistatin profile in inflammatory bowel disease.
Stadnicki A; Mazurek U; Plewka D; Wilczok T
Int Immunopharmacol; 2003 Jul; 3(7):939-44. PubMed ID: 12810351
[TBL] [Abstract][Full Text] [Related]
2. Immunolocalization and expression of kallistatin and tissue kallikrein in human inflammatory bowel disease.
Stadnicki A; Mazurek U; Gonciarz M; Plewka D; Nowaczyk G; Orchel J; Pastucha E; Plewka A; Wilczok T; Colman RW
Dig Dis Sci; 2003 Mar; 48(3):615-23. PubMed ID: 12757180
[TBL] [Abstract][Full Text] [Related]
3. Kallikrein-kinin system in inflammatory bowel diseases: Intestinal involvement and correlation with the degree of tissue inflammation.
Devani M; Vecchi M; Ferrero S; Avesani EC; Arizzi C; Chao L; Colman RW; Cugno M
Dig Liver Dis; 2005 Sep; 37(9):665-73. PubMed ID: 15949977
[TBL] [Abstract][Full Text] [Related]
4. Analysis of direct tissue isoelectric focused protein profiles of resected intestinal mucosa and endoscopic biopsies from patients with inflammatory bowel disease.
Szewczuk MR; Depew WT
Clin Invest Med; 1992 Feb; 15(1):49-59. PubMed ID: 1374000
[TBL] [Abstract][Full Text] [Related]
5. Intestinal oxidative damage in inflammatory bowel disease: semi-quantification, localization, and association with mucosal antioxidants.
Kruidenier L; Kuiper I; Lamers CB; Verspaget HW
J Pathol; 2003 Sep; 201(1):28-36. PubMed ID: 12950014
[TBL] [Abstract][Full Text] [Related]
6. Cytokine/chemokine messenger-RNA expression profiles in ulcerative colitis and Crohn's disease.
Autschbach F; Giese T; Gassler N; Sido B; Heuschen G; Heuschen U; Zuna I; Schulz P; Weckauf H; Berger I; Otto HF; Meuer SC
Virchows Arch; 2002 Nov; 441(5):500-13. PubMed ID: 12447682
[TBL] [Abstract][Full Text] [Related]
7. Kallikrein-kinin system activation in Crohn's disease: differences in intestinal and systemic markers.
Devani M; Cugno M; Vecchi M; Ferrero S; Di Berardino F; Avesani EC; de Franchis R; Colman RW
Am J Gastroenterol; 2002 Aug; 97(8):2026-32. PubMed ID: 12190172
[TBL] [Abstract][Full Text] [Related]
8. Quantitation of chemokines (MDC, TARC) expression in mucosa from Crohn's disease and ulcerative colitis.
Jugde F; Alizadeh M; Boissier C; Chantry D; Siproudhis L; Corbinais S; Quelvennec E; Dyard F; Campion JP; Gosselin M; Bretagne JF; Sémana G; Heresbach D
Eur Cytokine Netw; 2001; 12(3):468-77. PubMed ID: 11566628
[TBL] [Abstract][Full Text] [Related]
9. Expression of macrophage-colony stimulating factor in normal and inflammatory bowel disease intestine.
Klebl FH; Olsen JE; Jain S; Doe WF
J Pathol; 2001 Dec; 195(5):609-15. PubMed ID: 11745698
[TBL] [Abstract][Full Text] [Related]
10. Phagocyte-specific S100 proteins are released from affected mucosa and promote immune responses during inflammatory bowel disease.
Foell D; Wittkowski H; Ren Z; Turton J; Pang G; Daebritz J; Ehrchen J; Heidemann J; Borody T; Roth J; Clancy R
J Pathol; 2008 Oct; 216(2):183-92. PubMed ID: 18729068
[TBL] [Abstract][Full Text] [Related]
11. Suppression of Na+/H+ exchanger isoform-3 in human inflammatory bowel disease: lack of reversal by 5'-aminosalicylate treatment.
Siddique I; Hasan F; Khan I
Scand J Gastroenterol; 2009; 44(1):56-64. PubMed ID: 18785066
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of the fragile histidine triad (FHIT) gene in inflammatory bowel disease.
Wierzbicki PM; Adrych K; Kartanowicz D; Wypych J; Stanislawowski M; Zwolinska-Wcislo M; Celinski K; Skrodzka D; Godlewski J; Korybalski B; Smoczynski M; Kmiec Z
J Physiol Pharmacol; 2009 Oct; 60 Suppl 4():57-62. PubMed ID: 20083852
[TBL] [Abstract][Full Text] [Related]
13. Increased expression of tumor necrosis factor-alpha messenger RNA in the intestinal mucosa of inflammatory bowel disease, particularly in patients with disease in the inactive phase.
Akazawa A; Sakaida I; Higaki S; Kubo Y; Uchida K; Okita K
J Gastroenterol; 2002; 37(5):345-53. PubMed ID: 12051533
[TBL] [Abstract][Full Text] [Related]
14. [Annexin A2 expression in intestinal mucosa of patients with inflammatory bowel disease and its clinical implications].
Zhang Z; Zhao X; Lv C; Li C; Zhi F
Nan Fang Yi Ke Da Xue Xue Bao; 2012 Nov; 32(11):1548-52. PubMed ID: 23174572
[TBL] [Abstract][Full Text] [Related]
15. Substance P receptor expression in patients with inflammatory bowel disease. Determination by three different techniques, i.e., storage phosphor autoradiography, RT-PCR and immunohistochemistry.
ter Beek WP; Biemond I; Muller ES; van den Berg M; Lamers CB
Neuropeptides; 2007 Oct; 41(5):301-6. PubMed ID: 17602742
[TBL] [Abstract][Full Text] [Related]
16. Differential protein expression profile in the intestinal epithelium from patients with inflammatory bowel disease.
Shkoda A; Werner T; Daniel H; Gunckel M; Rogler G; Haller D
J Proteome Res; 2007 Mar; 6(3):1114-25. PubMed ID: 17330946
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive analysis of intestinal cytokine messenger RNA profile by real-time quantitative polymerase chain reaction in patients with inflammatory bowel disease.
Sawa Y; Oshitani N; Adachi K; Higuchi K; Matsumoto T; Arakawa T
Int J Mol Med; 2003 Feb; 11(2):175-9. PubMed ID: 12525873
[TBL] [Abstract][Full Text] [Related]
18. Increased expression of VEGF and CD146 in patients with inflammatory bowel disease.
Tsiolakidou G; Koutroubakis IE; Tzardi M; Kouroumalis EA
Dig Liver Dis; 2008 Aug; 40(8):673-9. PubMed ID: 18374637
[TBL] [Abstract][Full Text] [Related]
19. Changes in mRNA expression levels of solute carrier transporters in inflammatory bowel disease patients.
Wojtal KA; Eloranta JJ; Hruz P; Gutmann H; Drewe J; Staumann A; Beglinger C; Fried M; Kullak-Ublick GA; Vavricka SR
Drug Metab Dispos; 2009 Sep; 37(9):1871-7. PubMed ID: 19487253
[TBL] [Abstract][Full Text] [Related]
20. Fecal HMGB1 is a novel marker of intestinal mucosal inflammation in pediatric inflammatory bowel disease.
Vitali R; Stronati L; Negroni A; Di Nardo G; Pierdomenico M; del Giudice E; Rossi P; Cucchiara S
Am J Gastroenterol; 2011 Nov; 106(11):2029-40. PubMed ID: 21788990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
